

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>†</sup> <u>FERRARI RICHARD M</u>  (Last) (First) (Middle) <u>C/O PULMONX CORPORATION</u> <u>700 CHESAPEAKE DRIVE</u>  (Street) <u>REDWOOD CITY CA 94063</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Pulmonx Corp [ LUNG ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/05/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/05/2020		C		26,266	A	(1)	37,098	I	See Footnote <sup>(2)</sup>
Common Stock	10/05/2020		C		675,227	A	(1)	712,325	I	See Footnote <sup>(2)</sup>
Common Stock	10/05/2020		C		327,560	A	(1)	1,039,885	I	See Footnote <sup>(2)</sup>
Common Stock	10/05/2020		C		126,603	A	(1)	1,166,488	I	See Footnote <sup>(2)</sup>
Common Stock	10/05/2020		C		65,833	A	(1)	1,232,321	I	See Footnote <sup>(2)</sup>
Common Stock	10/05/2020		C		3,030	A	(1)	3,030	D	
Common Stock	10/05/2020		P		13,157	A	\$19	16,187	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-1 Preferred Stock	(1)	10/05/2020		C		26,266	(1)	(1)	Common Stock	26,266	\$0	0	I	See Footnote <sup>(2)</sup>	
Series B-1 Preferred Stock	(1)	10/05/2020		C		675,227	(1)	(1)	Common Stock	675,227	\$0	0	I	See Footnote <sup>(2)</sup>	
Series C-1 Preferred Stock	(1)	10/05/2020		C		327,560	(1)	(1)	Common Stock	327,560	\$0	0	I	See Footnote <sup>(2)</sup>	
Series D-1 Preferred Stock	(1)	10/05/2020		C		126,603	(1)	(1)	Common Stock	126,603	\$0	0	I	See Footnote <sup>(2)</sup>	
Series E-1 Preferred Stock	(1)	10/05/2020		C		65,833	(1)	(1)	Common Stock	65,833	\$0	0	I	See Footnote <sup>(2)</sup>	
Series G-1 Preferred Stock	(1)	10/05/2020		C		3,030	(1)	(1)	Common Stock	3,030	\$0	0	D		

**Explanation of Responses:**

- The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.
- The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shares voting and dispositive control over the shares held by De Novo

**Remarks:**

/s/ Mark Weeks, Attorney-In-Fact

10/05/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**